Natural History Studies Grants Program | FDA
The .gov means it’s official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. FDA Office of Orphan Products Development (OOPD) On this page: About the Program | What is a natural history study? | About the Awards | Related Links Unlike common diseases, there is little existing knowledge on the presentation, major limitations on day-to-day function, core unmet needs and course of most rare diseases which makes drug development challenging. To address this, it is critical to study the natural history of rare diseases. The FDA has funded natural history studies since 2016, to help address significant unmet medical needs for patients with rare diseases where there is often little knowledge on the progression of many rare diseases which m
On this page: About the Program | What is a natural history study? | About the Awards | Related Links About the Natural History Studies Grants Program Unlike common diseases, there is little existing knowledge on the presentation, major limitations on day-to-day function, core unmet needs and course of most rare diseases which makes drug development challenging. To address this, it is critical to study the natural history of rare diseases. The FDA has funded natural history studies since 2016, to help address significant unmet medical needs for patients with rare diseases where there is often
Explore this link on the map →related reading
- Gap Mapgap-map.org
- Rare Diseases at FDA | FDAfda.gov
- We Need a New Science of Progress - The Atlantictheatlantic.com
- Why is progress in biology so slow?sam-rodriques.com
- Unmet Needs Index — Biopharma Disease Prioritizationinsights.convoke.bio
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Real-World Evidence | FDAfda.gov
- Biotech’s Lost Archive | IFPifp.org
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Patient Registries - Registries for Evaluating Patient Outcomes - NCBI Bookshelfncbi.nlm.nih.gov
- NIH study suggests people with rare diseases face significantly higher health care costs | National Institutes of Health (NIH)nih.gov